PATENT CLAIM ANALYSIS

Application Number: 15967442
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "001850"]

Abstract:
Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Claim (Index 4):
The method of  claim 3 , wherein (ii) comprises administering the radionuclide-labeled 7\u03b1-(E-2\u2032-iodovinyl)-5\u03b1-dihydrotestosterone.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15508391', '15062740', '15346743', '15135151', '15222734']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7703892287001738
- 35 USC 102 Novelty (BERT): 0.5248570707531783
- Combined Prediction Score: 0.7458360129054743
- Mean Citation Score: 314.46507800000006
- Max Citation Score: 329.28775
- Similarity Product: 219.97453519114853

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test